So Friday afternoon Pacira Pharmaceuticals announced FDA approval of Exparel for nerve blocks in regional anesthesia. As a CRNA, this is a pretty big deal, I'd use this stuff every day if it weren't so expensive. Although the study is somewhat weak, because it tested its product (that is known to work) against a placebo, so of course it showed the product is a million times better than the placebo. The drug is also much more expensive than the drugs we use now for nerve blocks (as are most new drugs) and has a similar efficacy.
so I've been in a few pharmaceutical stocks and almost always notice a large spike with almost any FDA news, to me this seems like a huge deal, but i'm still pretty new to the game and don't want to get screwed.
it was already up 12% friday at close so i'm not sure if i missed the spike. I have an order placed but started thinking that maybe just because this is a potentially big deal to my profession doesn't necessarily mean its a big deal to the stock market.
anyone know anything about this company or have any thought or insight?
Submitted April 08, 2018 at 11:23AM by PropofLOL https://ift.tt/2EuvsyK
No comments:
Post a Comment